- Home
- UHT vs ZURA Comparison
UHT vs ZURA Comparison
Compare UHT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHT | ZURA |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.5M | 521.8M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | UHT | ZURA |
|---|---|---|
| Price | $42.61 | $5.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $43.00 | $13.00 |
| AVG Volume (30 Days) | 51.3K | ★ 617.7K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $33.52 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $0.99 |
| 52 Week High | $44.70 | $7.25 |
Technical Indicators
Market Signals| Indicator | UHT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 37.40 |
| Support Level | $41.96 | $3.33 |
| Resistance Level | $43.22 | $5.75 |
| Average True Range (ATR) | 0.78 | 0.32 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 71.17 | 7.54 |
Price Performance
Historical ComparisonAbout UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.